0000882095false00008820952026-05-042026-05-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 30, 2026
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware000-1973194-3047598
(State or Other Jurisdiction of Incorporation)(Commission File No.)(IRS Employer Identification No.)

333 Lakeside Drive, Foster City, California
(Address of principal executive offices)
94404
(Zip Code)
650-574-3000
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value, $0.001 per shareGILDThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Item 5.07    Submission of Matters to a Vote of Security Holders.
The 2026 annual meeting of stockholders (the “Annual Meeting”) of Gilead Sciences, Inc. (the “Company”) was held on April 30, 2026. Of the 1,241,222,013 shares of the Company’s common stock entitled to vote at the Annual Meeting, 1,130,179,690 shares were represented at the beginning of the meeting in person or by proxy, which constituted a quorum. The voting results are presented below.
The Company’s stockholders elected nine directors to serve for the next year and until their successors are elected and qualified. The votes regarding the election of directors were as follows:
NameVotes ForVotes AgainstAbstentionsBroker Non-Votes
Jacqueline K. Barton, Ph.D.1,013,176,696 21,056,724 938,657 95,008,389 
Jeffrey A. Bluestone, Ph.D.1,017,337,149 16,873,041 961,887 95,008,389 
Sandra J. Horning, M.D.1,002,426,858 31,078,619 1,666,600 95,008,389 
Kelly A. Kramer995,947,854 38,240,224 983,999 95,008,389 
Ted W. Love, M.D.1,016,607,688 17,592,385 972,004 95,008,389 
Harish Manwani995,710,468 38,469,820 991,789 95,008,389 
Daniel P. O’Day980,597,212 50,179,985 4,394,880 95,008,389 
Javier J. Rodriguez1,019,197,783 15,002,200 972,094 95,008,389 
Anthony Welters992,619,897 40,842,646 1,709,534 95,008,389 
The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received the following votes:
Votes For1,046,350,569 
Votes Against82,831,295 
Abstentions998,602 
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:
Votes For954,325,805 
Votes Against77,503,947 
Abstentions3,342,325 
Broker Non-Votes95,008,389 
The Company’s stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes:
Vote For970,290,586 
Vote Against62,501,433 
Abstentions2,380,058 
Broker Non-Votes 95,008,389 
The Company’s stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes:
Votes For280,044,780 
Votes Against752,716,225 
Abstentions2,411,072 
Broker Non-Votes95,008,389 



The Company’s stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes:
Votes For134,042,210 
Votes Against886,986,584 
Abstentions14,143,283 
Broker Non-Votes95,008,389 
The Company’s stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes:
Votes For7,262,421 
Votes Against1,022,330,186 
Abstentions5,579,470 
Broker Non-Votes95,008,389 

Item 9.01 - Financial Statements and Exhibits
(d): The following exhibits are being filed herewith:
Exhibit No.Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)









SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GILEAD SCIENCES, INC.
(Registrant)
/s/ Keeley M. Cain Wettan
Keeley M. Cain Wettan
Executive Vice President, General Counsel, Legal and Compliance, and Secretary
Date: May 04, 2026